Cascade Nanoreactor Based on Mo 2 C MXene for NIR-II-Activated Multimodal Therapy of Cancer
Molecular Pharmaceutics · 2026
DOI: 10.1021/acs.molpharmaceut.5c01663 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2026. Verfasst von Lu Zhao und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Chemistry and Chemical Engineering, Shanxi Provincial Key Laboratory of Chemical Biosensing, Shanxi Datong University, Datong 037009, P. R.…. Hauptthemen laut MEDLINE: Molybdenum, Neoplasms, Nanocomposites. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Scientific and Technological Projects of Datong City, Fund Program for the Scientific Activities of Selected Returned Overseas Professionals in Shanxi Province.
Abstract (Originalsprache)
The complexity and dynamic nature of the tumor microenvironment (TME) pose significant challenges to effective cancer therapy. Therefore, the development of nanocomposites capable of fully exploiting TME characteristics is crucial for achieving precise and efficient tumor treatment. Herein, the cascade nanoreactor PDA@Mo2C-MnO2-Au/Apt-M (PMMAA) was successfully constructed based on Mo2C MXene and nanozymes. This nanoreactor leveraged the TME to achieve NIR-II-triggered combined photothermal therapy and chemodynamic therapy (PTT/CDT) with active targeting capability. PMMAA exhibited a photothermal conversion efficiency of 41.89% under NIR-II laser irradiation, enabling efficient thermal ablation of tumor tissues. In the acidic TME, the loaded MnO2 NPs mediated Fenton-like reactions that selectively converted endogenous H2O2 into highly cytotoxic •OH, realizing intelligent TME-responsive CDT. Notably, the embedded Au NPs in the nanoreactor exhibited glucose oxidase-like activity, catalyzing the conversion of glucose into H2O2 and gluconic acid, thereby simultaneously elevating both H2O2 levels and local acidity to establish a self-amplifying catalytic cascade. This nanozymes-based cascade amplification effect significantly enhanced CDT efficacy by promoting •OH generation. Systematic evaluations demonstrated that the nanoreactor possessed dual enzyme-mimicking activities (POD-like and GOx-like), excellent biosafety, and remarkable tumor suppression effects. This study established a new paradigm for precision cancer therapy through the rational design of multifunctional nanozymes-enhanced CDT capable of dynamically modulating the TME.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Chemistry and Chemical Engineering, Shanxi Provincial Key Laboratory of Chemical Biosensing, Shanxi Datong University, Datong 037009, P. R. China.
- School of Agriculture and Life Science, Shanxi Datong University, Datong 037009, P. R. China.
ORCID-Profile: Yunfeng Bai, Feng Feng
Förderung
- National Natural Science Foundation of China
- Scientific and Technological Projects of Datong City
- Fund Program for the Scientific Activities of Selected Returned Overseas Professionals in Shanxi Province
- Fundamental Research Program of Shanxi Province
Zitieren
APA
Zhao, L., Li, J., Zhang, X., Bai, Y., & Feng, F. (2026). Cascade Nanoreactor Based on Mo 2 C MXene for NIR-II-Activated Multimodal Therapy of Cancer. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.5c01663
Vancouver
Zhao L, Li J, Zhang X, Bai Y, Feng F. Cascade Nanoreactor Based on Mo 2 C MXene for NIR-II-Activated Multimodal Therapy of Cancer. Molecular Pharmaceutics. 2026. doi:10.1021/acs.molpharmaceut.5c01663
BibTeX
@article{Zhao2026,
author = {Zhao, Lu and Li, Jianfeng and Zhang, Xuehui and Bai, Yunfeng and Feng, Feng},
title = {Cascade Nanoreactor Based on Mo 2 C MXene for NIR-II-Activated Multimodal Therapy of Cancer},
journal = {Molecular Pharmaceutics},
year = {2026},
doi = {10.1021/acs.molpharmaceut.5c01663}
}
EUVIMED